News >

Boosting Impact of Immunotherapy in Earlier NSCLC Settings

Caroline Seymour
Published: Monday, Nov 25, 2019

Jamie E. Chaft, MD

Jamie E. Chaft, MD

The improvement in progression-free survival (PFS) and overall survival (OS) with durvalumab (Imfinzi) after concurrent chemoradiotherapy in patients with stage III unresectable non–small cell lung cancer (NSCLC), and the preliminary signals of activity reported with checkpoint inhibitors in the neoadjuvant setting have shown the tremendous impact immunotherapy can have in earlier NSCLC stages, explained Jamie E. Chaft, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication